ERBB2 and breast carcinoma: Hence, the Food and Drug Administration has approved lapatinib, neratinib, trastuzumab, as well as other small molecule inhibitors and antibody-drug conjugate drugs for the treatment of HER2+ (overexpression/amplification) breast cancer patients.